Novartis is poised to market its gene therapy technology to treat spinal muscular atrophy , which often kills babies before they reach two years of age . A clinical trial of the therapy involved 12 babies , all of whom have passed their second birthday and achieved milestones in their lives . A new gene therapy made by Novartis is about to come to market with a potential price tag of $2 million, the Wall Street Journal reports. A potential cost of $ 2 m for the treatment has caused concern . However , drug companies are increasingly looking to alternative pricing models , such as doubling or tying prices to value , to address rising costs .
Novartis is poised to market its gene therapy technology to treat spinal muscular atrophy , which often kills babies before they reach two years of age . A clinical trial of the therapy involved 12 babies , all of whom have passed their second birthday and achieved milestones in their lives . A potential cost of $ 2 m for the treatment has caused concern . However , drug companies are increasingly looking to alternative pricing models , such as doubling or tying prices to value , to address rising costs .